Published in Radiat Oncol on June 22, 2014
First interim analysis of a randomised trial of whole brain radiotherapy in melanoma brain metastases confirms high data quality. BMC Res Notes (2015) 0.80
Retrospective Study of Metastatic Melanoma and Renal Cell Carcinoma to the Brain with Multivariate Analysis of Prognostic Pre-Treatment Clinical Factors. Int J Mol Sci (2016) 0.78
Novel risk scores for survival and intracranial failure in patients treated with radiosurgery alone to melanoma brain metastases. Radiat Oncol (2015) 0.77
miR-185 enhances the inhibition of proliferation and migration induced by ionizing radiation in melanoma. Oncol Lett (2017) 0.75
Cerebrovascular Remodeling and Neuroinflammation is a Late Effect of Radiation-Induced Brain Injury in Non-Human Primates. Radiat Res (2017) 0.75
Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol (2009) 9.90
Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys (1997) 8.58
Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol (2010) 6.15
Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys (2009) 6.11
A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys (2007) 5.07
Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol (2011) 4.12
Brain metastases: epidemiology and pathophysiology. J Neurooncol (2005) 3.83
Prognostic factors for survival in melanoma patients with brain metastases. Cancer (2010) 2.23
Multidisciplinary management of brain metastases. Oncologist (2007) 2.15
Radiosurgery for brain metastases: a score index for predicting prognosis. Int J Radiat Oncol Biol Phys (2000) 1.88
Radiosurgery for treatment of brain metastases: estimation of patient eligibility using three stratification systems. Int J Radiat Oncol Biol Phys (2004) 1.78
Determinants of survival in patients with brain metastases from cutaneous melanoma. Br J Cancer (2010) 1.37
Phase II trial of radiosurgery for one to three newly diagnosed brain metastases from renal cell carcinoma, melanoma, and sarcoma: an Eastern Cooperative Oncology Group study (E 6397). J Clin Oncol (2005) 1.28
Stereotactic radiosurgical treatment in 103 patients for 153 cerebral melanoma metastases. Int J Radiat Oncol Biol Phys (2004) 1.25
Stereotactic radiosurgery for cerebral metastatic melanoma: factors affecting local disease control and survival. Int J Radiat Oncol Biol Phys (1998) 1.22
Outcome predictors of Gamma Knife surgery for melanoma brain metastases. Clinical article. J Neurosurg (2010) 1.20
Outcome variation among "radioresistant" brain metastases treated with stereotactic radiosurgery. Neurosurgery (2005) 1.14
Multimodality treatment of melanoma brain metastases incorporating stereotactic radiosurgery (SRS). Cancer (2007) 1.13
Stereotactic radiosurgery for patients with "radioresistant" brain metastases. Neurosurgery (2002) 1.12
Metastatic melanoma to the brain: prognostic factors after gamma knife radiosurgery. Int J Radiat Oncol Biol Phys (2002) 1.07
Whole brain radiotherapy after local treatment of brain metastases in melanoma patients--a randomised phase III trial. BMC Cancer (2011) 1.03
Cyberknife for brain metastases of malignant melanoma and renal cell carcinoma. Neurosurgery (2009) 0.97
Importance of extracranial disease status and tumor subtype for patients undergoing radiosurgery for breast cancer brain metastases. Int J Radiat Oncol Biol Phys (2012) 0.89
Prognostic factors for overall survival after radiosurgery for brain metastases from melanoma. Am J Clin Oncol (2014) 0.86
Treatment of melanoma brain metastases: a new paradigm. Cancer J (2012) 0.86
Can current prognostic scores reliably guide treatment decisions in patients with brain metastases from malignant melanoma? J Cancer Res Ther (2011) 0.86
Whole-brain radiation therapy in melanoma: an open question. Lancet Oncol (2010) 0.78
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res (2009) 24.11
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 18.08
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 14.71
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med (2012) 13.48
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol (2014) 9.86
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med (2015) 8.80
Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med (2015) 8.64
Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet (2012) 7.61
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med (2015) 7.51
Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res (2008) 5.95
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol (2012) 5.32
Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst (2010) 5.23
A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature (2012) 5.02
Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst (2005) 4.63
Inactivation of the p53 pathway in retinoblastoma. Nature (2006) 4.57
BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res (2013) 4.28
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol (2008) 3.58
Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med (2013) 3.51
CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res (2013) 3.02
Discovery of an oncogenic activity in p27Kip1 that causes stem cell expansion and a multiple tumor phenotype. Genes Dev (2007) 3.00
MDMX: from bench to bedside. J Cell Sci (2007) 2.78
Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1. Clin Cancer Res (2012) 2.68
The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition. Clin Cancer Res (2012) 2.63
Differentiated horizontal interneurons clonally expand to form metastatic retinoblastoma in mice. Cell (2007) 2.61
KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res (2008) 2.57
Association of age at diagnosis and genetic mutations in patients with neuroblastoma. JAMA (2012) 2.49
From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer (2012) 2.46
Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Nat Rev Cancer (2013) 2.44
Bayesian adaptive randomized trial design for patients with recurrent glioblastoma. J Clin Oncol (2012) 2.39
Spectral CT with metal artifacts reduction software for improvement of tumor visibility in the vicinity of gold fiducial markers. Radiology (2012) 2.36
Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J Clin Oncol (2003) 2.36
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Case records of the Massachusetts General Hospital. Case 23-2012. A 59-year-old man with abdominal pain and weight loss. N Engl J Med (2012) 2.13
Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer (2014) 2.12
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci (2013) 2.03
Rb regulates proliferation and rod photoreceptor development in the mouse retina. Nat Genet (2004) 1.94
Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist (2013) 1.91
Synthetic lethality between Rb, p53 and Dicer or miR-17-92 in retinal progenitors suppresses retinoblastoma formation. Nat Cell Biol (2012) 1.89
Therapy-induced antibodies to MHC class I chain-related protein A antagonize immune suppression and stimulate antitumor cytotoxicity. Proc Natl Acad Sci U S A (2006) 1.88
Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute. Melanoma Res (2005) 1.87
Effect of isoflurane on neuronal apoptosis in rats subjected to focal cerebral ischemia. Anesth Analg (2004) 1.87
Identification and characterization of the first small molecule inhibitor of MDMX. J Biol Chem (2010) 1.85
Modulation of T-cell activation by malignant melanoma initiating cells. Cancer Res (2010) 1.83
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med (2015) 1.80
The first knockout mouse model of retinoblastoma. Cell Cycle (2004) 1.74
Six3-mediated auto repression and eye development requires its interaction with members of the Groucho-related family of co-repressors. Development (2002) 1.73
Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin Cancer Res (2008) 1.73
Coexpression of normally incompatible developmental pathways in retinoblastoma genesis. Cancer Cell (2011) 1.67
Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion. Blood (2013) 1.67
The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls. Neuropsychopharmacology (2007) 1.67
Anti-PD-1-Related Pneumonitis during Cancer Immunotherapy. N Engl J Med (2015) 1.64
Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancer. J Proteome Res (2008) 1.63
Obesity is an important determinant of baseline serum C-reactive protein concentration in monozygotic twins, independent of genetic influences. Circulation (2004) 1.59
Cells previously identified as retinal stem cells are pigmented ciliary epithelial cells. Proc Natl Acad Sci U S A (2009) 1.55
Compensation by tumor suppressor genes during retinal development in mice and humans. BMC Biol (2006) 1.54
Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements. Clin Cancer Res (2013) 1.53
A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States. Cancer J (2014) 1.51
Preparation and square wave electroporation of retinal explant cultures. Nat Protoc (2006) 1.48
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol (2013) 1.46
Melanoma, version 2.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw (2013) 1.44
Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell. Clin Cancer Res (2007) 1.44
Central nervous system complications of cancer therapy. J Support Oncol (2012) 1.43
Mutation-driven drug development in melanoma. Curr Opin Oncol (2010) 1.43
Radiation Therapy in the Management of Malignant Melanoma. Oncology (Williston Park) (2015) 1.38
Establishment of antitumor memory in humans using in vitro-educated CD8+ T cells. Sci Transl Med (2011) 1.37
Melanoma. J Natl Compr Canc Netw (2009) 1.37
Topotecan combination chemotherapy in two new rodent models of retinoblastoma. Clin Cancer Res (2005) 1.37
Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines. Immunol Rev (2008) 1.34
Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults. Neuro Oncol (2007) 1.34
Current clinical development of PI3K pathway inhibitors in glioblastoma. Neuro Oncol (2012) 1.33
Epithelial and stromal cathepsin K and CXCL14 expression in breast tumor progression. Clin Cancer Res (2008) 1.31
Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX. Blood (2002) 1.31
Retinoblastoma: one world, one vision. Pediatrics (2008) 1.29
Thermal spin-transfer torque in magnetoelectronic devices. Phys Rev Lett (2007) 1.28
When progressive disease does not mean treatment failure: reconsidering the criteria for progression. J Natl Cancer Inst (2012) 1.28
VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res (2008) 1.27
Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control. Clin Cancer Res (2013) 1.23
Targeting the p53 pathway in retinoblastoma with subconjunctival Nutlin-3a. Cancer Res (2011) 1.21
Melanoma brain metastasis: overview of current management and emerging targeted therapies. Expert Rev Neurother (2012) 1.19
Adult gliosarcoma: epidemiology, natural history, and factors associated with outcome. Neuro Oncol (2008) 1.19
The RTK/RAS/BRAF/PI3K pathways in melanoma: biology, small molecule inhibitors, and potential applications. Semin Oncol (2007) 1.14
Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction. Proc Natl Acad Sci U S A (2003) 1.14
Stereotactic body radiation therapy for liver metastases. Eur J Cancer (2009) 1.13
Stereotactic irradiation of the postoperative resection cavity for brain metastasis: a frameless linear accelerator-based case series and review of the technique. Int J Radiat Oncol Biol Phys (2010) 1.12
Moderate alcohol consumption, estrogen replacement therapy, and physical activity are associated with increased insulin sensitivity: is abdominal adiposity the mediator? Diabetes Care (2003) 1.12
Regulation of proliferation during central nervous system development. Semin Cell Dev Biol (2005) 1.11
Subconjunctival carboplatin and systemic topotecan treatment in preclinical models of retinoblastoma. Cancer (2010) 1.11
Anti-PD1 following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysis. Cancer Immunol Res (2013) 1.11
Eight-year update of a prospective study of wide excision alone for small low- or intermediate-grade ductal carcinoma in situ (DCIS). Breast Cancer Res Treat (2013) 1.10
Neuronal differentiation and synaptogenesis in retinoblastoma. Cancer Res (2007) 1.10
PKB/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas. J Neurooncol (2005) 1.09
Ipilimumab for patients with advanced mucosal melanoma. Oncologist (2013) 1.09